|   In the News

Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease


One problem with drugs for muscular disorders is that not enough medicine reaches the muscle, says Romesh Subramanian, CEO of Dyne Therapeutics. Subramanian’s startup has developed a way to target delivery of drugs to all muscle types, and it is emerging from stealth with $50 million in funding to advance its compounds toward human testing.

Read more.